87 results about "Epithelial barrier" patented technology

The invention discloses an application of a Piezo1 inhibitor in preparation of a medicine for treating necrotizing enterocolitis. The Piezo1 inhibitor can be applied in preparation of the medicine for treating the necrotizing enterocolitis. The Piezo1 inhibitor can also be applied to preparation of drugs for relieving NEC intestinal epithelial barrier injury. The Piezo1 inhibitor can also be applied to preparation of drugs for reducing calcium influx in intestinal epithelial cells and calcium / calmodulin dependent protein kinase activity. The application has the beneficial effects that the effect and mechanism of the Piezo1 for regulating and controlling the calcium ion influx and promoting the NEC severity degree by the calcium / calmodulin dependent protein kinase activity level are discussed for the first time from multiple aspects of animals, tissues, cells, molecules and the like, and the effect and mechanism of the activated intestinal epithelial cell Piezo1 in NEC inflammatory injury and barrier repair are clarified for the first time; the knockout of the gene can improve the NEC severity of mice, and a new intervention target is provided for clinical treatment.

The invention relates to the field of chemical analysis, and particularly discloses a method for detecting indole and derivatives thereof in serum and excrement. Before liquid chromatography-mass spectrometry detection, a methanol-water mixed solvent is adopted for extraction, and freeze grinding, ultrasonic treatment, standing, centrifugation and other steps are carried out. According to the pretreatment process, the influences of complex matrixes and more interfering substances are eliminated, more tryptophan metabolites are detected at the same time, the adopted pretreatment mode is simple, low in cost and environmentally friendly, and qualitative and quantitative detection of indole and derivatives thereof in complex biological samples can be achieved. The indole derivative has important significance in the fields of enhancing the integrity of the intestinal epithelial barrier, inhibiting neuroinflammation, improving insulin resistance and regulating and controlling the polarization direction of immune cells based on deep research of indole and the indole derivative.

The invention discloses a virus-like structure nano adapter and application thereof, on the basis of hepatitis B virus core protein Uniprot P03146 of which nucleic acid binding domains at 145-183 sites of a C tail end are removed, CBP as shown in SEQ ID NO.01 is respectively inserted into a spike part and an N tail end of the hepatitis B virus core protein Uniprot P03146. The invention is constructed based on collagen combined polypeptide CBP designed by bionic decorrin, aims to imitate the interaction between natural decorrin and collagenous fiber, can efficiently cross over corneal epithelium barrier and repair corneal stroma in a non-photo-crosslinking manner, and solves the limitation of existing clinical treatment.

The present invention relates to a recombinant Escherichia coli comprising at least one therapeutically active ingredient, preferably a therapeutic enzyme, in its outer membrane vesicles (OMV). The invention also relates to the use of this recombinant EcN to penetrate the intact intestinal epithelial barrier through OMV to deliver said therapeutically active ingredient, preferably a therapeutic enzyme, into the circulation. The OMV containing the therapeutic enzyme can stably catalyze various detoxification reactions in circulation, and is particularly used for clinically treating metabolic disorders (such as hyperuricemia) and the like.

The invention provides an apigenin nanoparticle preparation as well as a preparation method and application thereof. The preparation method comprises the following steps: weighing apigenin, dissolving the apigenin in an acetone solution containing a polylactic acid-glycolic acid copolymer, or dissolving the apigenin in an acetone solution containing the polylactic acid-glycolic acid copolymer and Eudragit S100, and uniformly stirring and mixing at room temperature to obtain a mixed solution; dropwise adding the mixed solution into a polyvinyl alcohol solution, carrying out ultrasonic treatment, and removing the solvent to prepare PANPs or PEANPs. The preparation method is simple, and the prepared PANPs and PEANPs are small in particle size and high in encapsulation efficiency, can effectively penetrate through intestinal epithelial barriers and promote internalization of apigenin into cells, have a good slow release characteristic, can remarkably improve the bioavailability of apigenin, and have a good treatment effect on inflammatory bowel diseases. PANPs has a better treatment effect on ulcerative colitis, and PEANPs has a better treatment effect on diffuse colitis.

The invention discloses a feed additive for preventing broiler necrotic enteritis, a preparation method and application, and relates to the technical field of feed. Comprising the following raw materials in parts by weight: 15-30 parts of plant essential oil, 40-60 parts of deoxycholic acid, 10-20 parts of vitamin D310, 3-8 parts of protein zinc, 2-6 parts of saccharomyces cerevisiae and 1-5 parts of zeolite powder. The feed additive provided by the invention is clear in component, stable in property, convenient to operate and control, easy to realize industrial production, and convenient to popularize and apply. By adopting the feed additive provided by the invention, the integrity of the intestinal epithelial barrier can be improved, the intestinal flora structure can be improved, the immunity of the organism can be improved, and necrotic enteritis of broilers can be effectively prevented.

The invention belongs to the technical field of medicines, and particularly discloses application of binding molecules of actin binding protein LASP1 in prevention and treatment of acute respiratory distress syndrome (ARDS). According to the invention, the LASP1-loaded nanoparticles are constructed, so that the problems that the drug is difficult to penetrate and easy to remove and degrade and the ARDS is difficult to treat are solved. According to the invention, through intranasal instillation of the HA-DA / BP / LASP1 nanoparticles, the level of inflammatory factors can be reduced, the alveolar epithelial barrier structure and function can be repaired, and the death rate of ARDS model mice can be reduced.

The application discloses a pachymic acid medicine composition for preventing and treating ulcerative colitis and application thereof, and relates to the technical field of medical application. The composition is prepared from the following components in parts: pachymic acid 100-500 parts, carboxymethyl cellulose solution 10-100 parts, medicinal adjuvant 10-120 parts, synergistic adjuvant 10-100 parts, solvent 10-50 parts, and purified water 100-120 parts. The pachymic acid is used as a clear monomer active ingredient to prepare a medicine for preventing and treating ulcerative colitis. Compared with the existing compound, extract or multi-component combination technical scheme, the application has the characteristics of clear active ingredient, relatively clear efficacy basis, convenient quality control and subsequent development. It is clear that the ulcerative colitis can be prevented and treated by inhibiting the cGAS-STING and NF-κB signal pathways, reducing the damage of the colon epithelial cells, inhibiting the release of pro-inflammatory factors, repairing the damaged intestinal mucus barrier and intestinal epithelial barrier, regulating the apoptosis balance of intestinal cells, and enhancing the antioxidant activity of the intestinal tract. The application plays a role in preventing and treating ulcerative colitis from multiple targets such as inflammation inhibition, barrier repair and antioxidant.

A method of testing a test substance in an in vitro model of a human tracheobronchial respiratory tract, includes: providing the in vitro model including a cell culture including airway epithelial cells (AECs), a basolateral compartment below the AECs and an apical compartment above the AECs, wherein the AECs form a barrier between the basolateral AND apical compartments; adding the test substance to the apical and / or basolateral compartment; adding a tracer to the basolateral compartment, which is fluorescent, has a molecular weight within 5 kDa of human albumin and is added before, during or after adding the test substance; incubating the cell culture system in a presence of the tracer; collecting at least one sample from the apical compartment; and measuring a fluorescence thereof to determine an effect of the test substance on the AECs. A kit is also disclosed.

The present invention belongs to the field of medicine, and in particular relates to the use of 1,6-anhydro-β-D-glucose in the preparation of drugs for maintaining the integrity of the colon epithelial barrier and crypts and for anti-colitis. The present invention detects the colitis-related metabolite 1,6-anhydro-β-D-glucose by detecting mouse serum, and applies it to mice. It is found that 1,6-anhydro-β-D-glucose can alleviate the weight loss and shortening of colon length in mice, reduce the disease score index (DAI), maintain the integrity of the colon epithelial barrier and crypts, and exert anti-inflammatory effects, thereby alleviating DSS-induced colitis. Therefore, 1,6-anhydro-β-D-glucose is expected to be used in the research and development of related drugs.

The present invention relates to a vaginal pharmaceutical composition and the methods and uses thereof including: treating and preventing genital inflammation in a subject; modifying the level of one or more of Lactobacillus crispatus, Lactobacillus gasseri, Lactobacillus Gardnerella, Lactobacillus jensenii and Lactobacillus iners in the genital microbiome of a subject; and maintaining or increasing the integrity of the cervicovaginal epithelial barrier in a subject.

Methods and materials relating to cultured choroid plexus organoids comprising: (a) an epithelium comprising a tight epithelial barrier; and / or (b) one or more cysts surrounded by an epithelium, plus other authentic features and markers.

The invention discloses a method for preparing a VA-ECMO lung injury treatment medicine by using ginkgolide A to regulate YARS1, and relates to the technical field of biological medicine, the method comprises the following steps: by using ginkgolide A as a YARS1 protein regulator, preparing the medicine for treating the VA-ECMO lung injury through virtual screening, binding affinity confirmation and cell efficacy confirmation; wherein the virtual screening is based on a protein structure model of YARS1, and bilobalide A with high affinity binding energy with YARS1 is screened out through molecular docking. It is proved that ginkgolide A can effectively improve the lung ventilation function by regulating YARS1, repair the alveolar epithelial barrier structure and inhibit the inflammatory oxidative stress reaction, and the lung injury treatment effect and clinical transformation safety under the support of VA-ECMO are improved.

The invention relates to an application of an MYOF protein in preparation of a product for preventing, relieving and / or treating acute lung injury. According to the application, the MYOF protein can be combined with GSDMD-NT, and up-regulation of expression of the MYOF protein can effectively inhibit activation of GSDMD and pyroptosis mediated by GSDMD, so that the MYOF protein has an application prospect in preparation of products for preventing, relieving and / or treating acute lung injury, and the technical problem that alveolar epithelial barriers are easily damaged during treatment can be solved.

Methods and materials relating to cultured choroid plexus organoids comprising: (a) an epithelium comprising a tight epithelial barrier; and / or (b) one or more cysts surrounded by an epithelium, plus other authentic features and markers.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine nano preparation and application thereof in preparation of a medicine for preventing / treating PM2.5 induced lung injury. The invention provides a traditional Chinese medicine nano preparation. The traditional Chinese medicine nano preparation comprises nobiletin, formononetin and a carrier. According to the traditional Chinese medicine nano preparation, the nobiletin and the formononetin are entrapped in the carrier to form the nano particles with uniform particle size and good dispersity, so that the problems of poor water solubility and low bioavailability of the medicine can be effectively improved, the lung targeted delivery is enhanced, and the residence time of the medicine in the lung is prolonged. According to the traditional Chinese medicine nano preparation, the expression of ZO-1, OCLN, E-cad and other connexins is remarkably improved by inhibiting the EGFR pathway, the alveolar epithelial barrier structure and function are protected, and the inflammatory response and oxidative stress induced by PM2.5 are relieved, so that the lung injury induced by PM2.5 is effectively prevented and treated.

The invention discloses a marker for diagnosing intestinal epithelial barrier injury induced by uremic toxin and application of the marker, and belongs to the technical field of biomedicine. Human colon cancer cells (Caco-2) are adopted to establish intestinal epithelial injury models under different urea treatment conditions, and the optimal concentration and time are screened through CCK-8 and immune blot. According to the present invention, RT-qPCR is adopted to detect the expression of lncRNANEAT1 and miR-122-5p, Westernblot and an immunofluorescence method are adopted to detect the expression of tight junction proteins Occludin, ZO-1 and Claudin-1, fluorescein sodium is adopted to detect the cell para-permeability of an intestinal epithelial injury model, and the combination of miR-122-5p with lncRNANEAT1 and Occludin is detected through bioinformatics analysis and dual-luciferase reporter gene analysis; the result shows that the lncRNANEAT1 can be used for protecting intestinal epithelial barrier injury induced by uremia toxin by regulating the miR-122-5p / Occludin axis. The discovery reveals an action mechanism of the lncRNANEAT1 in uremia toxin induced intestinal epithelial barrier injury, and provides a new thought and method for reducing complications of uremia patients and improving life quality.

The invention relates to the technical field of microorganisms, in particular to application of plant lactobacillus BD7807 in preparation of a product for treating intestinal barrier dysfunction. The product for treating intestinal barrier dysfunction can significantly improve Caco2 cell monolayer barrier injury induced by excessive fatty acid, alleviate body oxidative stress injury and whole body chronic low-degree inflammation caused by high fat diet, significantly enhance expression of tight junction genes and activity of proteins, enhance integrity of intestinal epithelial barrier, and improve the intestinal barrier dysfunction. And the market prospect is wide.

The application provides a kind of nasal mucosa in vitro culture method and culture fluid, the composition of the culture fluid includes Wnt / β-catenin signal pathway activator 0.1-20 μg / ml, fibroblast growth factor 10-150 ng / ml, TGF-β inhibitor 0.02-3 μg / ml, ROCK inhibitor 0.1-100 μmol / L, P38 MAPK inhibitor 0.1-1 μmol / L, serum-free additive 1X, N-acetyl cysteine 1-10 mmol / L, nicotinamide 1-20 mmol / L, GlutaMax additive 1X, antibiotic, DMEM / F12 culture medium 1X.The application can carry out in vitro culture to nasal mucosa, can keep at least 2 weeks of activity, and have complete epithelial barrier and immune system, can realize ex vivo nasal mucosa virus infection experiment.

The application discloses a traditional Chinese medicine composition with the effect of treating infantile recurrent respiratory tract infection and a preparation method thereof. Through a large amount of clinical practice, the application selects radix pseudostellariae, fried atractylodes, fried rhizoma atractylodis, agastache, levisticus, lonicera, radix scrophulariae, carbonized wheat bran, calcined osseous, ephedra root as raw materials, and is prepared into an oral or external dosage form according to weight ratio. The application has the effects of transporting the spleen, preventing the invasion of pathogenic factors, and consolidating the surface and stopping sweating, and is used for infantile recurrent respiratory tract infection with the syndrome of the spleen failing to transport and the lung and defensive system failing to consolidate. The application is verified by clinical tests, has remarkable curative effect, no toxic side effect, and good safety. Animal experiment researches show that the traditional Chinese medicine composition can effectively relieve the chronic inflammation level of model mice, improve the airway epithelial barrier damage, improve the body's ability to resist pathogenic factors, and reduce the risk of infection. The application can fill the market blank of treating infantile recurrent respiratory tract infection diseases based on the theory of 'four seasons with the spleen being strong and not being invaded by pathogenic factors' and 'the spleen being strong is not about tonifying but about transportation', and has great development prospect.

The application belongs to the technical field of medicines, and particularly relates to application of alpha-asarone in preparation of a medicine for treating allergic rhinitis. The application aims at the problems of single drug target, prominent safety hazards and inability to block pathological progress from the root in the existing medicines for treating allergic rhinitis, takes alpha-asarone as an active ingredient, inhibits excessive activation of an inflammation pathway by activating an Nrf2 / HO-1 signal axis, and bidirectionally regulates expression balance of GPX4 and ACSL4 to inhibit ferroptosis and damage of a nasal epithelial barrier. Animal experiments prove that the alpha-asarone can significantly reduce allergic behaviors of model mice, relieve inflammation of nasal mucosa, reverse tissue remodeling, has high safety, and can be prepared into oral or nasal preparations, and provides a new treatment scheme with multiple target points for allergic rhinitis.

The present invention provides a preparation method for extracting volatile oil of Chimonanthus chinensis leaves by ultrasonic-assisted steam distillation and its application in improving ulcerative colitis drugs. The method includes crushing Chimonanthus chinensis leaves to a specific particle size and then performing ultrasonic treatment and steam distillation under optimized conditions, and finally achieving 2.5% to 4% high-efficiency extraction. Volatile oil is rich in phellandrene, α-terpineol and (+)-limonene, accounting for more than 50% of the total mass. Pharmacological experiments show that this volatile oil can significantly reduce the levels of pro-inflammatory factors interleukin 6 (IL-6), interleukin 1β (IL-1β) and tumor necrosis factor α (TNF-α) in mouse serum, increase anti-inflammatory factor interleukin 10 (IL-10); increase the expression of tight junction protein ZO-1, protect the integrity of mouse intestinal epithelial barrier; and significantly downregulate the expression of proline hydroxylase 3 factor of HIF-1 pathway to inhibit inflammation.

The invention relates to the field of biological medicine, in particular to glycyrrhiza polysaccharide, a preparation method thereof and application of the glycyrrhiza polysaccharide to preparation of medicine for treating acute lung injury. The preparation method comprises the following steps: adding water into the radix liquiritiae, boiling, and extracting to obtain a water extract; and adding an alcoholic solution with the volume concentration of 70-75% into the water extract to carry out alcohol precipitation treatment, wherein the volume ratio of the water extract to the alcoholic solution is (1.20-1.30): 1. The glycyrrhiza polysaccharide provided by the invention has the effects of protecting lung tissue epithelial barrier, resisting oxidation and inflammation, regulating intestinal flora and the like. The preparation method is simple, convenient and efficient, the product forms are diversified, the medicine is suitable for clinical and animal models, and a multi-target intervention strategy is provided for acute lung injury treatment.

The invention belongs to the technical field of animal nutrition and feed, discloses an application of a Fuzhuan tea extract in prevention of vomitoxin-caused piglet health injury, and particularly relates to an application of the Fuzhuan tea extract as a feed additive in prevention or improvement of piglet health injury. The feed additive can effectively reduce negative effects on weaned piglets caused by excessive vomitoxin in the feed, wherein the negative effects comprise growth performance reduction, diarrhea rate increase, intestinal morphology damage, intestinal cell proliferation inhibition, intestinal epithelial barrier injury, immune disorder, abnormal liver function and excessive oxidative stress and inflammatory response.

The invention discloses a compound traditional Chinese medicine water decoction for protecting an airway epithelial barrier and a preparation method and application thereof, the compound traditional Chinese medicine water decoction is a water decoction of a herba epimedii and fructus ligustri lucidi medicine pair, the compound traditional Chinese medicine water decoction comprises 7-14 parts by weight of herba epimedii and 7-14 parts by weight of fructus ligustri lucidi, the herba epimedii adopts roasted herba epimedii, and the fructus ligustri lucidi adopts wine fructus ligustri lucidi. The compound traditional Chinese medicine water decoction not only can inhibit airway epithelial cell apoptosis and relieve airway epithelial injury, but also can up-regulate expression of epithelial connexin caused by inflammatory injury, so that the epithelial barrier function is improved, the airway epithelial barrier steady state is maintained, and pathogens and allergens are prevented from entering. The use and popularization of the compound traditional Chinese medicine water decoction not only contribute to preventing airway inflammation, but also can relieve the incidence and severity of chronic and refractory respiratory system diseases, and has important significance for perfecting the treatment strategy of the existing respiratory system inflammatory diseases and improving the control rate.

The present invention relates to vaginal pharmaceutical compositions and methods and uses thereof, including: treating and preventing genital inflammation in a subject; modulating the level of one or more of Lactobacillus crispatus, Lactobacillus gasseri, Lactobacillus gardneri, Lactobacillus jensenii, and Lactobacillus iners in the genital microbiome of a subject; and maintaining or improving the integrity of the cervical-vaginal epithelial barrier in a subject.

The invention discloses a bionic gastric mucosa micro-barrier structure, comprising: a bottom microfluidic channel for simulating a submucosal vascular network; the middle gastric epithelial cell layer is used for simulating a mucous membrane epithelial barrier and comprises a matrix layer, quaternary functional cells, a culture medium and a pH buffer module; and the surface dynamic mucus layer is used for simulating a mucous membrane protective barrier and comprises a vagus neurotransmitter simulant, exogenous mucus and a pressure sensor. According to the invention, continuous nutrition supply is provided for the middle gastric epithelial cell layer through the bottom microfluidic channel, the survival and functions of cells are maintained, and accurate tracking of the transgastric mucosa transport process is realized. A function collaborative network is formed through quaternary cells, the secretion volume and the injury state are monitored in real time, regulatory factors are dynamically adjusted, and it is ensured that a cell layer can still maintain the barrier function stable under external interference. When foreign matter impact or food friction signals are recognized through the pressure sensor, the pump speed is instantly increased, and local mucus loss is rapidly supplemented.

The application discloses a kind of drug composition of synergistic targeting MMP-9 path and STING path and application thereof, belong to the technical field of ophthalmic drugs.The drug composition includes the final concentration 5~90 μM of Marimastat, the final concentration 2.5~10 μM of SN-011, the final concentration 0.1 vol % of DMSO and sterile PBS buffer solution.The drug composition of the application can efficiently, safely treat moderate to severe dry eye, effectively improve tear film stability, repair corneal epithelial barrier, inhibit ocular surface chronic inflammation, while reducing the risk of disease recurrence.

The invention discloses a bronchial asthma treatment drug based on RBX1 inhibition and application thereof, and finds that expression of RBX1 in asthma patients and disease models is up-regulated, and the expression level of RBX1 is in positive correlation with airway epithelial barrier injury and active oxygen accumulation degree, which indicates that RBX1 is a key new target for asthma treatment. On the basis of the compound Z226407860 and the compound Z4189742053, the condition that the expression of the RBX1 can be effectively inhibited is further proved. In an in-vitro model, the compounds not only significantly reduce the protein level of RBX1, but also show a good synergistic treatment effect: the compounds can effectively relieve the injury of the airway epithelial barrier and promote the integrity recovery of the barrier, and can inhibit the excessive accumulation of active oxygen at the same time, so that the asthma process is intervened from two correlative core pathological links. The research provides a solid experimental basis and a candidate compound with a clear prospect for developing a therapeutic drug which aims at bronchial asthma and has a brand new action mechanism.

The present disclosure relates to therapeutic proteins and pharmaceutical compositions containing the proteins that are useful for treating various human diseases. In certain aspects, the disclosed therapeutic proteins are useful for treating human gastrointestinal inflammatory diseases and gastrointestinal conditions associated with impaired epithelial cell barrier function or integrity. Furthermore, the disclosed therapeutic proteins are useful for treating human inflammatory bowel diseases, including Crohn's disease and ulcerative colitis, among others.